Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Response To Global HIV Must Be Stronger To Save IP System – Kessler

Executive Summary

Pharmaceutical manufacturers need to do more than rely on President Bush's global AIDS relief initiative if they want to protect the international patent system, former FDA commissioner David Kessler says

You may also be interested in...

PhRMA Prepares For More TRIPS Import Talks; U.S. Lays Out “Interim Plan”

The Pharmaceutical Research & Manufacturers of America expects TRIPS negotiations on the importation of drugs made under compulsory license to resume within several weeks

WTO Patent Declaration Supports Incentives For Rx Companies

The World Trade Organization declaration on pharmaceutical patents includes language encouraging developed countries to provide incentives to industry to improve public health in developing nations

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts